GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as ...

Just last week, (the exact date I cannot recall) the lights at my house flickered around 12 midnight for a while and then ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Like the rest of you, I’ve seen a ton of weird Super Bowl commercials in my life. Heck. If I’m being honest, more than a few of them have come during this Super Bowl itself. I guess that’s ...

Inspiratm Technologies OXY B.H.N. Ltd. ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today announced positive initial results from its previously reported ...

Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing ...

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, an innovative, FDA-cleared delivery platform, today ...

DMT S.A. (BP 270, Savoie-Technolac, F-73375 Le Bourget du Lac), which was only founded in 1990 by its current owners, Darlet and Marchante, has emerged as one of the world's leading suppliers of ...

Aya will release its fourth quarter and full year 2024 financial and operational results before market open on March 28, 2025 and will host a conference call shortly afterwards. Details of the call ...